Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | CD44 | P16070 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14403476 | 0.85 | NPC1 (0.63) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL15883113 | 0.85 | NPC1 (0.67) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL14877791 | 0.85 | NPC1 (0.67) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL20634694 | 0.82 | NPC1 (0.56) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL19010013 | 0.81 | NPC1 (0.74) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL28674499 | 0.81 | NPC1 (0.65) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL27865678 | 0.81 | NPC1 (0.65) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL23585151 | 0.81 | NPC1 (0.58) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL28484683 | 0.81 | NPC1 (0.61) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL28484685 | 0.81 | NPC1 (0.61) | NPC1MAPTRAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186570-B2 | Intermediate of eribulin and preparation method therefor | SELECTION BIOSCIENCE LLC (CN) | 2021-11-30 | — | — | US | disclosed |
| US-20200095235-A1 | INTERMEDIATE OF ERIBULIN AND PREPARATION METHOD THEREFOR | SELECTION BIOSCIENCE LLC (CN) | 2020-03-26 | — | — | US | disclosed |
| US-10494388-B2 | Compounds useful in the synthesis of halichondrin B analogs | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-12-03 | — | — | US | disclosed |
| US-20180162885-A1 | COMPOUNDS USEFUL IN THE SYNTHESIS OF HALICHONDRIN B ANALOGS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200095235-A1 | INTERMEDIATE OF ERIBULIN AND PREPARATION METHOD THEREFOR | ERLIN1, ERLIN2, CYP4F11 | NPC1 2108/4885MAPT 3947/4885RAB9A 2701/4885 |
| US-20180162885-A1 | COMPOUNDS USEFUL IN THE SYNTHESIS OF HALICHONDRIN B ANALOGS | ERLIN1, ERLIN2, MAN1B1 | NPC1 1125/4885MAPT 2696/4885RAB9A 1053/4885 |
| US-10494388-B2 | Compounds useful in the synthesis of halichondrin B analogs | ERLIN1, ERLIN2, MAN1B1 | NPC1 1125/4885MAPT 2696/4885RAB9A 1053/4885 |
| US-11186570-B2 | Intermediate of eribulin and preparation method therefor | ERLIN1, ERLIN2, CYP4F11 | NPC1 2108/4885MAPT 3947/4885RAB9A 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.